Campbell & CO Investment Adviser LLC Has $629,000 Holdings in DexCom, Inc. $DXCM

Campbell & CO Investment Adviser LLC trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 63.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 9,355 shares of the medical device company’s stock after selling 16,421 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in DexCom were worth $629,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC raised its position in DexCom by 2.5% in the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after purchasing an additional 169 shares during the last quarter. Inspire Investing LLC grew its holdings in shares of DexCom by 6.1% during the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after purchasing an additional 180 shares during the last quarter. Integrated Wealth Concepts LLC increased its stake in shares of DexCom by 6.3% in the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after buying an additional 196 shares during the period. STF Management LP raised its holdings in DexCom by 5.5% in the 2nd quarter. STF Management LP now owns 4,041 shares of the medical device company’s stock valued at $353,000 after buying an additional 211 shares during the last quarter. Finally, Simmons Bank boosted its position in DexCom by 6.8% during the 2nd quarter. Simmons Bank now owns 3,439 shares of the medical device company’s stock worth $300,000 after buying an additional 219 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach bought 18,200 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was acquired at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the purchase, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $59.05, for a total value of $171,599.30. Following the completion of the transaction, the director directly owned 35,088 shares in the company, valued at approximately $2,071,946.40. This trade represents a 7.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 7,866 shares of company stock valued at $448,177 over the last 90 days. Company insiders own 0.32% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $72.11 on Thursday. The firm has a market cap of $28.12 billion, a price-to-earnings ratio of 40.06, a PEG ratio of 1.27 and a beta of 1.48. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25. The company’s fifty day simple moving average is $65.83 and its 200 day simple moving average is $71.30.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period last year, the business posted $0.45 EPS. The business’s revenue was up 21.6% compared to the same quarter last year. On average, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Canaccord Genuity Group set a $99.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Friday, October 31st. Citigroup reissued a “buy” rating and issued a $77.00 price objective (up previously from $75.00) on shares of DexCom in a research note on Thursday, December 11th. BTIG Research decreased their price objective on DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a report on Friday, October 31st. JPMorgan Chase & Co. lowered their target price on DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Friday, October 31st. Finally, Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 16th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $86.30.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.